Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Patents 400show all

  • 119
    A61K - Preparations for medical, dental, or toilet purposes
  • 118
    C07D - Heterocyclic compounds
  • 33
    Y02A - Technologies for adaptation to climate change
  • 25
    C12N - Microorganisms or enzymes
  • 19
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 18
    B01D - Separation
  • 15
    C40B - Combinatorial chemistry
  • 14
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 12
    C07H - Sugars

Clinical Trials 17show all

7N/A4Phase 14Phase 21Early Phase 11Phase 3

SEC Filings show all


17
8-K

8
D

4
10-Q

1
10-K

1
S-1

Contact Information

4215 Sorrento Valley Blvd.
San Diego, CA 92121
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$215,727,86951-1002012-11-06Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2005-05-12$31,000,000Series CRoche Venture FundGimv, Canadian Medical Discoveries Fund, Perseus-Soros Biopharmaceutical Fund, Avalon Ventures, GeneChem, Forward Ventures
2000-12-31$18,800,000Series BForward VenturesAvalon Ventures, Perseus-Soros Biopharmaceutical Fund
2010-04-15$12,000,000Series D
2012-11-06$50,000,000Series UnknownOrbiMedForward Ventures, Roche Venture Fund, Aisling Capital, GrowthWorks Capital, MedImmune Ventures, Apposite Capital, Gimv, Radius Ventures
2010-10-15$14,999,327Debt Financing
2000-12-01$2,000,000Seed
2007-11-14$49,300,000Series DApposite CapitalGeneChem, Forward Ventures, Roche Venture Fund, OrbiMed, Avalon Ventures, Radius Ventures, Horizon Technology Finance, Gimv, NovaQuest, Perseus-Soros Biopharmaceutical Fund, MedImmune Ventures
2011-06-10$30,000,000Series DApposite CapitalNovaQuest, OrbiMed, Gimv, GrowthWorks Capital, Radius Ventures, MedImmune Ventures, Roche Venture Fund, Forward Ventures
2009-06-05$6,428,542Debt Financing
2003-10-23$1,200,000Series Unknown

SEC Form D Funding Events

DateOfferedSoldType
2012-11-09$44,814,271$22,206,064Equity, Option to Acquire, Security to be Acquired
2012-05-30$11,482,825$7,066,803Option to Acquire, Security to be Acquired
2011-07-11$30,026,638$22,000,006Equity, Option to Acquire, Security to be Acquired
2010-10-15$15,913,126$14,999,327Debt, Option to Acquire, Security to be Acquired
2010-04-15$13,440,000$12,000,000Debt, Option to Acquire, Security to be Acquired
2009-07-30$2,360,980$0Option to Acquire, Security to be Acquired
2009-06-29$19,717,220$6,428,542Debt, Option to Acquire, Security to be Acquired
2007-11-13Unknown Unknown Other (Paper Filing)

Key Executives

  • M. Scott Salka
    Executive Officer, Director
  • Steven Elms
    Director
  • Standish M. Fleming
    Director
  • Allan Marchington
    Director
  • Alan J. Lewis, Ph.D.
    Director
  • Alexander Zukiwski
    Director
  • Saiid Zarrabian
    Director
  • Wendell Wierenga, Ph.D.
    Executive Officer
  • Kerry A. Kelly, J.D.
    Executive Officer
  • Joseph Regan
    Director
  • Christopher J. Morl
    Executive Officer
  • Isai Peimer
    Director
  • Alan Fuhrman
    Executive Officer
  • Faheem Hasnain
    Director
  • Michael A. Martino
    Executive Officer, Director
  • Athena Countouriotis
    Executive Officer
  • David P. Bonita
    Director